Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Discover how poorly made PowerPoint presentations waste millions in productivity, drain team focus, and increase business ...

From scholarly lectures to TED-style talks, from academic posters to interactive workshops, we engage with audiences ranging from field experts to the general public. This multi-faceted approach to ...

All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...

today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu ...

PowerPoint’s layouts and templates hold the key to transforming your ideas into visually striking presentations that captivate your audience. These tools aren’t just for designers—they’re ...

Session A-2 Room 339: Leverage AI in Psychology: Finding a Use Case Presentation 1: Finding a Use Case: Building a Scheduling GPT: Olivia Velez, Psychology Presentation 2: Finding a Use Case: Natural ...

Sydnexis, Inc., ( www.sydnexis.com) a pre-commercial stage biopharmaceutical company, announces that three abstracts have been accepted for poster presentations at the upcoming Association for ...

Title: Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials: a new ...

today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah.

today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City ...

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and ...